Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

457 Features
The PharmiWeb.com e:HR Awards 2006

25 Oct 06

Recognizing excellence in the application of an e-business approach in pharma and biotech HR in Europe.
Mike Wood

Drug pipeline suggests glimmer of hope for SLE sufferers

20 Oct 06

While there have been no new treatments approved for systemic lupus erythematosus (SLE) in almost 40 years, there are some promising treatments currently in the development pipeline. Unfortunately, the ambiguity surrounding the requirements of clinical trials is preventing these drugs from being approved. However, faced with few alternatives, that hasn't prevented physicians using them off-label.
Datamonitor

Has the current approach to pharmaceutical sales passed its expiry date?

17 Oct 06

It’s another Monday practice meeting, the usual drug representative has been roped in to provide lunch and is cooling her heels waiting for the team to finish morning surgery. The usual non-descript pile of sandwiches from the local bakery is stacked on the table and the registrar who has finished early has already picked the best sandwiches...
Ian Mckenzie - PharmiWeb.com Field Reporter

Ovarian cancer: platinum-based therapy still the gold standard

13 Oct 06

Despite being the most common cause of death from gynecological tumors, ovarian cancer does not attract the same level of R&D interest as more prevalent tumor types. While surgery still plays a central role in the treatment of ovarian cancer, platinum-based therapy, in particular, carboplatin in combination with paclitaxel, remains the mainstay of cytotoxic treatment for ovarian cancer.
Datamonitor

Schering-Plough: new fungicide gets US approval

06 Oct 06

Noxafil is a new fungicide developed by Schering-Plough. Already marketed in Europe, it has now received US approval on the basis of clinical trials showing its superiority over fluconazole in preventing invasive fungal infections in immuno-compromised patients. Revenues derived from this new drug will help bolster Schering-Plough's Infectious Diseases division.
Datamonitor

Researchers find new clue to treating diabetes

05 Oct 06

Researchers in Auckland have decoded the structure of a molecule that may provide clues for a new type of diabetes drug.
Emma Timewell

Age is no longer a factor

02 Oct 06

From October 1st 2006 the Employment Equality (Age) Regulations 2006 - is coming in to force, making it illegal in the UK to recruit or select candidates based on their age and to discriminate based on age whilst in employment rather than based on skills and competencies. This will apply to discrimination againt young and old, and it WILL dramatically affect recruitment and employment in the UK.
Mike Wood

Mid pharma looks outside itself to drive revenue

28 Sep 06

In 2005, 44% of 'mid pharma' revenues were derived from products that have been discovered outside of the in-house development pipelines. In fact, even in the absence of any further external sourcing between now and 2010, the dependence on revenues of products that came from external pipelines will continue to increase, coming to stand at 49% by 2010.
Datamonitor

DPP-4 inhibitors Galvus and Januvia will be the first oral drugs tackling Type 2 diabetes via the incretin response: how do they compare?

27 Sep 06

A new DPP-4 inhibitor class of oral anti-diabetic medicines, working by the novel mechanism of incretin enhancement, is poised to revolutionise the management of Type 2 diabetes. Data presented at a recent European Association for the Study of Diabetes meeting suggest they will help fill the unmet need for effective anti-diabetic drugs without unacceptable side effects. Numerous agents are in development with two, Galvus (vildagliptin, Novartis) and Januvia (sitagliptin, Merck) awaiting approval
Olwen Glynn Owen - PharmiWeb Field Reporter

International Conference on Silicone Elastomes Highlights Future Growth

25 Sep 06

Rapra Technology’s First International Conference on Silicone Elastomers took place in Frankfurt on 19-20 September attracting over 120 delegates from as far away as Australia, Brazil, Russia and the US. Presentations covered silicone elastomer materials, liquid silicone rubber, the processing of silicone elastomers, additives and finishing for silicone elastomers. Delegates praised the breadth of the programme content and the practical nature of many of the papers.
Sharon Garrington

The dangers of counterfeit anti-infectives

22 Sep 06

Counterfeit anti-infective drugs are a serious issue, causing significant morbidity and mortality, particularly in poorer countries, and having a huge financial impact on pharmaceutical firms worldwide. To make matters worse, high-tech solutions proposed and applied in the developed world are not easily transferable to the regions of Africa and Asia, where more than 50% of drugs may be fake.
Datamonitor

GSK: given green light to restrict Greek drug supply

20 Sep 06

The Hellenic Competition Committee has issued GSK with a favorable decision, indicating that it can restrict the supply of pharmaceuticals to wholesalers to prevent parallel importation of these drugs, without breaking competition laws. This is an important step for legally restricting parallel importation from one of Europe's biggest parallel trade markets, as Datamonitor's Dr Mark Belsey discovers…
Datamonitor

Meet the Country

20 Sep 06

Running clinical trials and recruiting experienced clinical personnel in the UK has certainly challenged many senior managers and recruiters over the past year. At a recent UK conference, both the Association of the British Pharmaceutical Industry (ABPI) and a UK pharmaceutical website were quoted as stating that there continues to be a skills shortage across all disciplines; a lack of long-term educational investment and less development of the existing talent pool were cited as the main reaso
Iain Jessup

PHASE IV CLINICAL TRIALS: Post Marketing Studies

19 Sep 06

Strategic Research Institute’s Phase IV Clinical Trials (PCT) conference features a fully packed informational two day event organized into a series of discussions focusing on the major Phase IV and Patient Recruitment/ Retention issues of today.
Amy Yueh

Pay for Performance: Strategies for Achieving Value and Improving Health Outcomes

19 Sep 06

GAIN VALUABLE INSIGHT INTO: • How CMS’ movement toward P4P will Impact Healthcare and Payors Nationwide • Large Employer HR Strategy: How Aligning Incentives and Creating a Health • Information Exchange will Reduce your Healthcare Spend • Health Plans: How Data, Transparency and Consumers will Affect your P4P Initiatives
Seth Fritts

Medicare Part D: What is the Future?

19 Sep 06

Highlights Include: Five Presentations from CMS including an Update on the 2007 Landscape Understanding the Short- and Long-Term Impact of Part D Strategies for Driving Senior Enrollment Innovative Approaches to Public & Private Partnerships Analyzing Patient Perceptions of Out-of-Pocket Costs The Importance of Pharmacoeconomic Data Securing Favorable Formulary Coverage in the Part D Environment The Future of Employer Plans
Amy Yueh

We are opening our doors here at i3

31 Aug 06

We would like to invite you to join us here at our offices in Maidenhead, Berkshire from 10.30 onwards to 14.30.
Sarah Kettlewell

Lean Documentation 5

30 Aug 06

In an earlier field report, we looked at some of the issues surrounding manufacturing process instructions (MPIs) and manufacturing process records (MPRs). I want to look at the issue of recording data in MPRs in more detail, as the format of your MPR has a huge impact on its usability and therefore the error rate.
PharmiWeb.com Field Reporter: Jo Hills

Movers and Shakers of the Pharma Industry - Paul Hawkins

23 Aug 06

Paul Hawkins, the General Secretary for the Health and Beauty Association, tells us his philosophy for career progression and how the H&BA’s new website will help them to progress. The website itself promotes HBA’s attempt to bring Health and Beauty companies together in debating and discussing how to develop and adapt the industry to meet changing customer and consumer needs. Paul hopes the move towards e-business will do just that.
Freya Eden-Ellis

Graduates Entering the Pharmaceutical Industry

22 Aug 06

You may not exactly be breaking into the gold vaults at Fort Knox, scaling the heights of MI5 à la James Bond or hacking into The Pentagon security system, but you want to enter the pharmaceutical industry, which can be nearly as difficult.
Freya Eden-Ellis

US healthcare payers turn to reimbursement to contain costs

18 Aug 06

With overall healthcare spending set to continue rising, payers are implementing cost containment measures, increasing the importance of developing a robust and flexible pricing and reimbursement (P&R) strategy. In formulating and adapting a P&R strategy, it is vital for drug developers to understand how P&R fits into the US healthcare market, and to identify the different types of P&R controls.
Datamonitor

Candidate Profile: Paul Collins

09 Aug 06

Candidate Profile: Paul Collins Current Job Title: Clinical Project Manager II Department: Clinical Commenced with ICON: July 1997
Mike Wood, Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - Andy Sarfas

08 Aug 06

Andy Sarfas is our mover and shaker of the week. He is the Global Internet Business Manager for Reckitt Benckiser.
Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - David Mitchell

08 Aug 06

David Mitchell is the Commercial Director at McNeil Consumer Healthcare, a company that produces remedies for self-treatment available at pharmacies and supermarket stores.
Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - Alex Bishop

08 Aug 06

Alex Bishop is the IT Business Manager at Pfizer, the largest supplier of medicines to the NHS.
Freya Eden-Ellis

Diverse challenges await generics industry

04 Aug 06

Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.
Datamonitor

Lean Documentation 4

03 Aug 06

Manufacturing Instructions and Records: Operators are expected to follow manufacturing instructions to produce a product that meets the required specification. Typically these instructions will be written by technical experts, the chemical engineers who were responsible for the technology transfer, the process validation and so on.
PharmiWeb.com Field Reporter: Joanna Hills

Networking Tips

03 Aug 06

Networking: What is it and How do you do it?
Jim Melling - Field Reporter

Elidel Eczema Cream: Dr Mark Ballard Answers Our Questions

01 Aug 06

Dr Mark Ballard, the Medical Director of Respiratory and Dermatology Therapeutic Areas at the Novartis Pharmaceuticals Corporation answers our questions about their eczema cream Elidel.
Freya Eden-Ellis

Call for guidelines on when to stop or continue drug treatment for Alzheimer’s Disease

01 Aug 06

Doctors taking part in a survey on Alzheimer’s Disease (AD) management have called for clear and consistent guidelines on diagnosis and treatment of the condition to be drawn up as a matter of urgency. The survey was sponsored by Eisai Europe Ltd and Pfizer Inc, who market the cholinesterase inhibitor Aricept (donepezil), and was presented during the International Conference on Alzheimer’s Disease and Related Disorders.
Olwen Glynn Owen – Pharmiweb Field Reporter

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.